Ken Griffin Neogenomics Inc Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Neogenomics Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 135,000 shares of NEO stock, worth $2.03 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
135,000
Previous 152,000
11.18%
Holding current value
$2.03 Million
Previous $2.11 Million
5.55%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding NEO
# of Institutions
295Shares Held
125MCall Options Held
698KPut Options Held
120K-
Black Rock Inc. New York, NY19.7MShares$296 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA14MShares$211 Million0.0% of portfolio
-
Brown Advisory Inc6.89MShares$104 Million0.13% of portfolio
-
Janus Henderson Group PLC London, X06.6MShares$99.3 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.54MShares$98.4 Million0.06% of portfolio
About NEOGENOMICS INC
- Ticker NEO
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 125,796,000
- Market Cap $1.89B
- Description
- NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytoge...